In a solid tumor model, in which CD19 antigen was engineered in human breast cancer cell line MDA-231, host mice receiving hNELFB-expressing CAR-T cells exhibited smaller tumor growth than those with parental CAR-T cells (Supplementary Fig. 8e). This evidence concerns the gene CD19 and neoplasm.